AI-assisted, human-published
09/30/2024 /Technology
C2N Diagnostics Secures $15 Million Investment for Alzheimer’s Blood Biomarker Tests
C2N's investment from GHR Foundation aims to advance the development of less invasive blood biomarker tests targeting tau tangle pathology in Alzheimer’s disease, offering potential benefits in diagnosis, disease staging, and therapeutic development.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com